Biontech SE ADR Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/27/2026)
| Balance Sheet | Total Assets | 21,988,600,000.00 | ROE | 87.43 % |
| Balance Sheet | Total Equity | 19,224,200,000.00 | ROA | -5.17 % |
| Cashflow | Capital Expenditures | -749,000,000.00 | P/FCF | -67.85 |
| Cashflow | Free Cash Flow | -293,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 456,000,000.00 | P/CF | 43.60 |
| Income | Earnings per Share (diluted) | -4.70 | Div. Yield | – |
| Income | Net Income | -1,136,100,000.00 | P/E | -17.50 |
| Income | Shares Outstanding | 251,325,000.00 | P/B | 1.03 |
| Income | Total Revenue | 2,869,900,000.00 | P/S | 6.93 |
Ratios calculated on: 10/14/2026
Company Description
BioNTech SE, a biotechnology company, develops and markets immunotherapies against cancer and other infectious diseases. The company is involved in the development of FixVac product candidates, including BNT111, which is in the Phase I clinical trial for advanced melanoma. BNT112, which is in Phase I / II trial in prostate cancer; BNT113, which is in Phase I for the treatment of HPV + head and neck cancer; BNT114, which is in Phase I clinical trial for triple negative breast cancer; BNT115 in Phase I Ovarian Cancer Study; and BNT116, which is in a preclinical lane for non-small cell lung cancer. It is also developing neo-antigen-specific immunotherapies such as RO7198457, which is in the Phase II clinical trial for first-line melanoma as well as the Phase I clinical trial for the treatment of multiple solid tumors. Intratumoral mRNA immunotherapy with SAR441000 in Phase I clinical trial for solid tumors; and BNT141 and BNT142 for the treatment of multiple solid tumors. The company is also developing riboCytokines, which include BNT151, BNT152, and BNT152, for several solid tumors. chimeric antigen receptor T cell immunotherapies such as BNT211 for treating multiple solid tumors and BNT212 for treating pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I / II clinical trials for the treatment of multiple solid tumors. It is also developing MVT-5873, an IgG1 monoclonal antibody that is in Phase I / II clinical trials in pancreatic cancer. BNT411, product candidate for low-molecular immunomodulators for solid tumors; and immunotherapies for infectious diseases and protein replacement therapies for rare diseases. The company works with Genentech, Inc .; Sanofi S. A .; Genmab A / S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc .; Shanghai Fosun Pharmaceutical (Group) Co., Ltd .; Regeneron Pharmaceuticals, Inc .; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.biontech.de
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more